MARKET

INVA

INVA

Innoviva
NASDAQ
22.41
+0.68
+3.13%
Opening 15:41 05/20 EDT
OPEN
21.90
PREV CLOSE
21.73
HIGH
22.52
LOW
21.84
VOLUME
611.99K
TURNOVER
--
52 WEEK HIGH
25.15
52 WEEK LOW
16.52
MARKET CAP
1.65B
P/E (TTM)
3.712
1D
5D
1M
3M
1Y
5Y
1D
Innoviva Appoints Josephine Linden to Strengthen Board Oversight
TipRanks · 1d ago
Innoviva names Josephine Linden to board after Small, DiPaolo resign
PUBT · 1d ago
Weekly Report: what happened at INVA last week (0511-0515)?
Weekly Report · 2d ago
Innoviva management to meet with BTIG
TipRanks · 6d ago
Weekly Report: what happened at INVA last week (0504-0508)?
Weekly Report · 05/11 10:30
What Innoviva (INVA)'s Profit Rebound and ESOP Share Filing Means For Shareholders
Simply Wall St · 05/11 01:14
Innoviva (INVA) Q1 Profit Swing Challenges Bearish Earnings Decline Narratives
Simply Wall St · 05/07 23:37
Innoviva (INVA) Receives a Rating Update from a Top Analyst
TipRanks · 05/07 11:53
More
About INVA
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.

Webull offers Innoviva Inc stock information, including NASDAQ: INVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INVA stock methods without spending real money on the virtual paper trading platform.